Video Summary - Testosterone replacement therapy: compelling use cases, side effects, and optimal dosing schedules

Summary of key wellness & TRT optimization strategies

Free vs. total testosterone
- Total testosterone is largely bound (especially to SHBG and albumin); only a small fraction is free/unbound.
- Lab estimates of free testosterone are calculated using measured binding proteins, which can introduce error.
Age-related decline isn’t universal
- Total testosterone may decline gradually (on average ~1%/year after mid-adulthood), while free testosterone may decline faster (~2–3%/year).
- Some men maintain high levels even later in life, so low testosterone at age 45 does not automatically mean TRT is required.

Most compelling case: primary hypogonadism
- High LH/FSH with low testosterone suggests the testes aren’t responding adequately to pituitary signaling.
- Before starting TRT, the speaker emphasizes ruling out structural or functional issues, such as:
  - Testicular ultrasound
  - Potential contributors like varicoceles
If LH/FSH are low (secondary issue), lifestyle factors may be the driver
- Common correlates mentioned:
  - Poor sleep
  - Elevated glucocorticoids (stress hormones)—a category harder to fix because it often requires behavior change, not just medication.

Typical starting range
- Discussed as a reasonable “entry” point:
  - ~80–120 mg/week
- Another mentioned general safe start idea:
  - ~100–120 mg/week, then reassess
Adjust based on response and what’s actually low
- Evaluate whether symptoms align more closely with total testosterone vs free testosterone.
- Consider high SHBG as a possible reason for low free T despite an “okay” total T.

Avoid “big bolus” weekly dosing
- Once-weekly dosing can create large peaks and troughs and is described as less physiologic.
- The goal is to mimic natural daily/dial-like rhythm (morning higher, fluctuating through the day).
Minimum “better than once weekly” guidance
- Once weekly = bare minimum
- Twice weekly = minimum for decent steadiness, especially with good quality oversight
Twice weekly often beats every-other-week
- A “dramatic difference” was described when moving from every 2 weeks → twice weekly.
- Diminishing returns at very high frequency were acknowledged (e.g., daily may add less incremental benefit than the big jump from infrequent dosing).

Why more frequent dosing may reduce side effects
- Frequent injections may reduce:
  - Aromatization spikes (estrogen surges)
  - DHT/5-alpha reduction spikes
  - Downstream problems such as sleep disruption and hematologic effects (e.g., hematocrit/erythrocytes)
Daily dosing example
- A protocol example mentioned: ~15 mg/day (not always practical due to needle/volume logistics).
- In the speaker’s experience, daily dosing reduced FSH/LH suppression, suggesting fewer peak-driven effects.

Timing of bloodwork
- Natural testosterone varies across the day; labs may capture only one point in the fluctuation.
- With injections, literature-based “trough” timing may not match real-world optimization.
Watch for estrogen-related effects
- Example given:
  - Some men need an aromatase inhibitor (AI) on less frequent dosing to prevent gynecomastia.
  - When dividing the same weekly dose into more frequent injections, they may be able to stop the AI.

Testosterone ester choice
- Cypionate vs enanthate
  - Claimed differences aren’t clearly decisive in the speaker’s view.
  - While pharmacokinetics differ, frequency can make ester differences less important once dosing is frequent enough.
Why FDA-formulated products are preferred over compounding
- The emphasis is that compounded products carry “dark side” risks.
- FDA options (certain branded forms) may improve consistency and reduce compounding variability.

Preferred approach (speaker’s practice bias)
- The speaker advises subcutaneous (subQ), while noting evidence is limited.
Reasoning given
- SubQ may show higher measured totals partly because blood draws are often done later after a shot.
- SubQ may behave like more sustained release due to absorption dynamics in fat tissue.
Practical conclusion
- With sufficiently frequent dosing (e.g., around every other day), the difference between subQ and IM becomes less important.
- With infrequent dosing (e.g., once weekly), subQ may be more concerning if oil volume is high enough to cause lumps/irritation.

No specific individual presenter name is provided in the subtitles (the conversation is between “you” and “I/Dr.” without identifying names).
Mentioned guest: Mo Cara (discussed enosed/nesto and nasal testosterone context).
Product/brand referenced:
- Testo / nesto (nasal testosterone; described as very short half-life)
- Zad (pre-loaded testosterone enanthate option)
Estradiol / DHT / AIs are referenced as concepts/therapeutic categories (not as sources).